1. Introduction {#sec1}
===============

The amyloid precursor protein (APP) is a type I membrane protein. After ectodomain shedding by *β*-secretase, the carboxyl-terminal fragment (*β*CTF) of APP becomes a direct substrate of *γ*-secretase and is processed into the amyloid *β* protein (A*β*) and the APP intracellular domain (AICD) \[[@B1]--[@B5]\]. *γ*-secretase is an enigmatic protease composed of presenilin 1/2, nicastrin, Aph-1, and Pen-2 that catalyzes proteolysis in the hydrophobic environment of the lipid bilayer \[[@B6]--[@B15]\]. Currently, over 50 molecules are reported as *γ*-secretase substrates, which reflects the physiological importance of this enzyme \[[@B16]\]. For instance, the Notch receptor on the plasma membrane is cleaved by *γ*-secretase upon ligand binding and the liberated Notch intracellular domain (NICD) translocates into the nucleus and activates the expression of transcription factors to suppress neuronal differentiation \[[@B17], [@B18]\]. This indicates that inhibition of *γ*-secretase for suppression of A*β* production causes harmful side effects. To avoid this risk in anti-Alzheimer\'s disease (AD) therapeutics, it is very important to elucidate the molecular mechanism underlying *γ*-secretase-dependent proteolysis. Recently, it was revealed that *γ*-secretase forms a hydrophilic pore and three water-accessible cavities \[[@B19]--[@B23]\]. Here, we review the progress of research on the mechanism underlying the proteolysis of the transmembrane domain of *β*CTF.

2. Discovery of *ε*-Cleavage during APP Processing {#sec2}
==================================================

After the *β*-secretase-dependent cleavage of APP, the ectodomain of APP is released into the extracellular space and *β*CTF (as a stub in the lipid bilayer) is the direct substrate of *γ*-secretase \[[@B2], [@B3], [@B24]\]. *β*CTF is composed of 99 amino acids and is eventually processed into the 38--43-residue-long A*β*, suggesting that the counterparts of those A*β* species should contain 56--61 residues \[[@B4], [@B25]--[@B29]\]. However, 50-51-residue-long AICDs were identified that correspond to residues 49--99 and 50--99 of *β*CTF (AICD49--99 and AICD50--99), instead of 56--61-residue-long species ([Figure 1](#fig1){ref-type="fig"}) \[[@B30]--[@B32]\]. These AICD species were suppressed by L-685,458, a transition state analogue *γ*-secretase inhibitor, and by expression of a dominant-negative mutant of presenilin (PS), suggesting that *γ*-secretase cleaves *β*CTF not only in the middle of the transmembrane domain (*γ*-cleavage), but also at sites close to the membrane/cytoplasm boundary (*ε*-cleavage), releasing AICD49--99 and AICD50--99. *ε*-Cleavage sites are analogues of the Notch S3 cleavage site, which is located at the membrane, near the cytoplasm ([Figure 1](#fig1){ref-type="fig"}). Cleavages similar to the APP *ε*-cleavage were identified in other proteins, such as amyloid precursor-like protein 1 (APLP-1), APLP-2, CD44, Delta 1, E-cadherin, ErbB4, and LRP1 \[[@B30], [@B33]--[@B37]\]. It is reasonable to consider that the water molecules required for proteolysis have access to the catalytic center of *γ*-secretase from the cytoplasm, rather than from the extracellular space, and that *ε*-cleavage precedes *γ*-cleavage during APP processing.

3. Relationship between *γ*- and *ε*-Cleavage {#sec3}
=============================================

CHO cells expressing familial AD (FAD) mutants of PS or APP increase production ratio of A*β*42 (A*β*43) to A*β*40 compared to cells expressing wild-type PS or APP these longer A*β* species are more hydrophobic and more prone to form neurotoxic aggregates. CHO cells expressing wild-type PS preferentially release AICD50--99, whereas those expressing a subset of familial AD (FAD) mutants of PS or APP exhibit an increased proportion of AICD49--99 ([Figure 2(a)](#fig2){ref-type="fig"}) \[[@B38]\]. As those FAD mutations cause an increase in the A*β*42/A*β*40 ratio, a potential link between *γ*- and *ε*-cleavage was assumed. To test this, we expressed A*β*49 and A*β*48, which are potential counterparts of AICD50--99 and AICD49--99, respectively, in CHO cells. The cells expressing A*β*49 predominantly secreted A*β*40, whereas those expressing A*β*48 exhibited a significantly increased proportion of A*β*42/A*β*40 ([Figure 2(b)](#fig2){ref-type="fig"}) \[[@B39]\]. These data indicate that *ε*-cleavage sites determine the preference for *γ*- and *ε*-cleavage sites to produce A*β*40 and A*β*42. Long A*β* species, A*β*49 and A*β*48, have been identified in cell lysates and mouse brain extracts, which suggests that *ε*-cleavage is the first cleavage of *β*CTF to produce A*β* by *γ*-secretase \[[@B40]\]. On the other hand, *ε*-cleavage can be considered as endopeptidase activity of *γ*-secretase. FAD mutations did not consistently impair the endopeptidase activity on APP, Notch, ErbB4, and N-Cadherin, but altered *γ*-cleavage of APP, especially fourth cleavage to produce A*β*40 and A*β*38 from A*β*43 and A*β*42, respectively \[[@B41]\]. Such dissociation between *ε*-cleavage and *γ*-cleavage was also proposed by Quintero-Monzon et al. \[[@B42]\].

4. Tripeptide Hypothesis {#sec4}
========================

Treatment with N-\[N-(3,5-difluorophenacetyl)-L-alanyl\]-(S)-phenylglycine t-butyl ester (DAPT), a *γ*-secretase inhibitor, suppressed extracellular A*β* in cells expressing APP \[[@B43]\]. The levels of the intracellular A*β*40 and A*β*42 species also decreased after DAPT treatment; however, intracellular A*β*43 and A*β*46 increased in a dose-dependent manner \[[@B40], [@B44], [@B45]\]. Tryptophan substitutions of *γ*-cleavage site (41--43) of APP attenuated A*β* secretion, but accumulated A*β*45 species in cell lysate. Tryptophan substitutions of *ε*-cleavage site (48--52) of APP decreased A*β* production and allowed longer AICD46--99 production. Tryptophan substitutions of *ξ*-cleavage site (45--47) also suppressed A*β* production. These substitution studies also implied successive cleavage of APP for A*β* production after *ε*-cleavage \[[@B46]\].

*γ*-Secretase containing mature nicastrin accumulates in lipid rafts, which indicates that active *γ*-secretase mainly localizes to the lipid raft of cells \[[@B47]\]. Lipid rafts are an ideal material to investigate A*β* production in the membrane environment. A*β*46 was the dominant species in a lipid raft isolated from DAPT-treated cells. Interestingly, incubating this lipid raft in the absence of DAPT resulted in production of A*β*40 and A*β*43, but not of A*β*42 \[[@B48]\]. These data suggest that A*β*46 is mainly converted into A*β*40 by releasing VIV and IAT tripeptides (successive tripeptide release, tripeptide hypothesis; A*β*40 product line) ([Figure 3(a)](#fig3){ref-type="fig"}). On the other hand, CHO cells expressing an FAD mutant of presenilin 2 exhibited a decrease in intracellular A*β*42 and a concomitant increase in intracellular A*β*45 levels in the presence of DAPT, suggesting that A*β*45 is a precursor of A*β*42 by releasing TVI (A*β*42 product line) ([Figure 3(a)](#fig3){ref-type="fig"}) \[[@B49]\]. It is reasonable to consider that two major product lines lead to A*β*40 and A*β*42 production ([Figure 3(a)](#fig3){ref-type="fig"}).

5. Identification of Tri- and Tetrapeptides Released from *β*CTF {#sec5}
================================================================

The most effective approach to confirm tripeptide release from *β*CTF is the identification of those tripeptides directly in the reaction mixture of A*β* production. CHAPSO soluble *γ*-secretase was isolated and incubated with the *β*CTF substrate. LC-MS/MS analysis identified five major tripeptides, and *γ*-secretase inhibitors abolished the production of these molecules. ITL, VIV, and IAT were predicted tripeptides in the A*β*40 product line ([Figure 3(a)](#fig3){ref-type="fig"}). The amounts of A*β*40 and A*β*43 in the reaction mixture, as assessed using Western blotting, corresponded roughly to the predicted A*β*40 and A*β*43 levels, respectively \[[@B50]\]. VIT and TVI were also detected in the A*β*42 product line, as predicted ([Figure 3(a)](#fig3){ref-type="fig"}). Interestingly, the VVIA tetrapeptide was detected in the reaction mixture only in the absence of *γ*-secretase inhibitors ([Figure 3(b)](#fig3){ref-type="fig"}). We postulated that VVIA was released from A*β*42 to produce A*β*38. No significant difference was detected between the level of A*β*42 by Western blot quantification and that by LC-MS/MS quantitative estimation. These results indicate that *γ*-secretase releases tri- and tetrapeptides successively upon *ε*-cleavage of *β*CTF, to produce A*β* species. These tri- and tetrapeptides released from *β*CTF were detected even in the lipid raft fraction (Takami, unpublished observation).

6. Is Tripeptide Release a General Property of Substrate Cleavage by *γ*-Secretase? {#sec6}
===================================================================================

Successive tripeptide release was observed in *β*CTF processing by *γ*-secretase. We also found that *γ*-secretase released tri- and tetrapeptides successively from *α*CTF substrate (Takami, unpublished observation). Recently, tripeptide spacing of endoproteolysis on presenilin has been reported \[[@B51]\]. These suggest that successive tri- and tetrapeptide release is a general property of *γ*-secretase-mediated intramembrane proteolysis.

Yanagida et al. reported that APLP-1 was also cleaved into three A*β*-like peptides \[[@B52]\]. As three *ε*-like cleavages are known, it is likely that APLP-1 is processed in three product lines by successive tripeptide release \[[@B30]\] ([Figure 4](#fig4){ref-type="fig"}). The transmembrane domain of mNotch-1 is cleaved by *γ*-secretase after ectodomain shedding to liberate NICD (S3 cleavage). NICD containing V1744 was found as the prominent species produced by S3 cleavage \[[@B53]\]. To date, it seems reasonable to suppose that there is a single cleavage site in S3. *γ*-Secretase also cleaves mNotch-1 at the lumen-membrane boundary (S4 cleavage) to release Notch *β* peptides (N*β*) ([Figure 4](#fig4){ref-type="fig"}) \[[@B56], [@B54], [@B55]\]. Fenofibrate treatment increased the proportion of N*β*25, but not that of N*β*21, which implies that N*β*25 and N*β*21 correspond to A*β*42 and A*β*40, respectively \[[@B55]\]. However, it is unlikely that several N*β* product lines exist in Notch processing because of the single S3 site. The production of N*β* species may not fit the tripeptide-processing model ([Figure 4](#fig4){ref-type="fig"}). CD44 is cleaved not only at the membrane-cytoplasm boundary, but also at the middle of the transmembrane domain, which results in the release of A*β*-like peptides \[[@B33], [@B57]\]. Similar to Notch, the processing of the CD44 transmembrane domain may not fit the tripeptide-processing model ([Figure 4](#fig4){ref-type="fig"}).

7. Conclusion and Perspectives {#sec7}
==============================

The tripeptide hypothesis was confirmed in the processing of the APP transmembrane domain, which accounts for the production of A*β* species. Although the physiological significance of the multiple cleavage of the transmembrane domain is unknown, it is important to illustrate the cleavage mechanisms of other *γ*-secretase substrates, because the limitation of this stepwise mechanism would help to elucidate the substrate-specific inhibition of A*β* production. As shown in [Figure 4](#fig4){ref-type="fig"}, APLP-1 may be cleaved by tripeptide release; however, Notch and CD44 do not fit this processing model \[[@B56], [@B57]\]. *γ*-Secretase is widely believed to be a promiscuous protease; however, the cleavage mechanisms of APP and Notch, at least, seem to be different ([Figure 4](#fig4){ref-type="fig"}), which indicates that *γ*-secretase distinguishes substrates during proteolysis. Perhaps absence of helix breaker glycine residues in mid-portion of transmembrane domain allows multiple S4 cleavages even after single S3 cleavage in Notch. From this point of view, uncovering the mechanisms underlying *γ*-secretase-dependent cleavage offers a basis for new therapeutic approaches that are aimed at substrate-specific A*β* inhibition.
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![*β*CTF is cleaved at the membrane-cytoplasm boundary and not in the middle of the transmembrane domain (*ε*-cleavage), to release the AICD49--99 and AICD50--99 species. The production of AICD species was inhibited in the presence of a *γ*-secretase inhibitor. *ε*-Cleavage is analogous to the S3 cleavage of mNotch-1. Red indicates the transmembrane domain.](IJAD2012-591392.001){#fig1}

![Relationship between *γ*- and *ε*-cleavage. (a) Cells expressing wild-type PS or APP predominantly produce A*β*40 and AICD50--99, while cells expressing a FAD mutant of PS or APP exhibited increased proportion of A*β*42 and AICD49--99. (b) Expression of A*β*49 results in an increase in A*β*40/A*β*42 ratio, whereas expression of A*β*48 leads to opposite results. ↗ increase, ↘ decrease.](IJAD2012-591392.002){#fig2}

![Tri- and tetrapeptide release from *β*CTF. (a) Upon *ε*-cleavage at *ε*48, *γ*-secretase releases the VIT and TVI tripeptides successively to produce A*β*42. (b) In the A*β*40 product line, after *ε*-cleavage at *ε*49, *β*CTF is converted into A*β*40 by releasing ITL, VIV, and IAT. A*β*42 is a direct substrate during A*β*38 production, which acts by releasing the VVIA tetrapeptide.](IJAD2012-591392.003){#fig3}

![Multiple cleavage sites on the transmembrane domain of *γ*-secretase substrates. APP \[[@B50]\], APLP-1 \[[@B30], [@B52]\], mNotch-1 \[[@B56]\], and CD44 \[[@B57]\].](IJAD2012-591392.004){#fig4}
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